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Introduction 
The majority of previously untreated patients with early phase B-cell 
chronic lymphocytic leukemia (B-CLL) expects a long-lasting indolent 
course of the disease. Long-time survival of these patients does not differ 
from that of an age- and sex-matched control population [1]. However, 
approximately 30% of the patients wi l l have progressive disease within 2 
years after establishment of diagnosis. Diffuse bone marrow involvement 
[2], lymphocyte doubling time < 12 months [3], and serum levels of thy-
midine kinase > 5 U/l [4] have been identified as risk factors for progres-
sion. Treatment with chlorambucil during the early phase of the disease 
revealed no benefit with respect to survival, but led to an increased risk for 
secondary malignancies [1]. Therefore, early stage B-CLL usually is not 
treated until progression has occurred. 
In pilot studies, interferon-a (IFN-a) was shown to have antileukemic 
activity in early stage B-CLL [5-8] whereas only marginal or no beneficial 
effects were reported in advanced stage disease [9, 10]. Here, we report on 
our own experiences obtained from a pilot study with IFN-a in early stage 
B-CLL. Furthermore, we present first results of a still ongoing randomized 
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multicenter trial. Encouraged by the results of our pilot study, this trial was 
activated to examine the possible benefit of an IFN-a treatment in early 
stage disease at high risk for progression. We wi l l also discuss future con-
cepts dealing with IFN-a in the treatment of B-CLL. 
IFN-a in a Pilot Study on B-CLL 
Patient Characteristics 
Prompted by the obvious efficacy of IFN-a in hairy cell leukemia [11], a pilot study in 
B-CLL was initiated [7, 12]. Nine patients with previously untreated early stage B - C L L (4 
females, 5 males) were included in this phase I I trial. Median age was 48 years (range 42-58 
years). They all had Binet stage A disease [13], according to Rai stages varying from 0 to I I 
114]. Median time from first diagnosis was 16 months (range 2-65 months). Four patients 
had a lymphocyte doubling time (LDT) < 12 months. A diffuse bone marrow involvement 
was found in another 2 patients. Overall, the tumor load was considered to be low, since the 
total circulating lymphocyte count in each patient did not exceed 50,000 1/ul at the time of 
recruitment for the study. 
Treatment 
Treatment consisted of 5 x 106 IU IFN-a subcutaneously (Intron A®, supplied by 
Essex-Pharma. Munich, FRG) 3 times weekly. Duration of treatment has been in the range of 
15-36 months. Treatment was overall well tolerated. In 6 patients toxic side effects included 
flu-like symptoms, which did not exceed W H O grade I I . While in 2 patients depression was 
observed, another 2 patients did not experience any toxic side effects. 
Results 
A l l patients responded to IFN-a with a decrease of their lymphocyte 
count. However, the lymphocyte count increased again despite continued 
IFN-a treatment in 1 patient 3 weeks after initiation of therapy. Splenome-
galy resolved in 1 patient, and this particular patient turned from Rai stage 
II to stage I disease. A rise of immunoglobulin levels was observed in 3 
patients, and in 4 patients HLA-DR expression on monocytes was dou-
bled. Four patients achieved a partial remission according to the remission 
criteria proposed by Cheson et al. [15], whereas another 4 patients had 
stable disease. 
Conclusions 
This pilot study showed the antileukemic efficacy of IFN-a in early 
stage B-CLL. The high rate of responding patients (8 out of 9) was in 
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Table I . Pilot studies on IFN-a in B-CLL 
Author Patients CR PR Ref. 
Foon et al. 18 0 2 9 
O'Connell et al. 4 0 1 16 
Pangalis and Griva 10 1 4 6 
Talpaz et al. 10 0 3 10 
Rozman et al. 10 0 8 8 
Ziegler-Heitbrock et al. 9 0 8 7 
accordance with some previous reports [6, 8], but in striking contrast to 
other findings [9], However, that latter report discussed data obtained in a 
trial on patients with advanced stage and in some cases pretreated but 
refractory B-CLL. One may therefore speculate that a low tumor load and 
lack of prior cytotoxic therapy as in our patients could be a prerequisite 
condition for the effectiveness of IFN-a. (A summary of published remis-
sion rates in B-CLL treated with IFN-a is listed in table 1.) 
Of major interest was the finding that patients with a L D T < 12 
months and with a diffuse bone marrow involvement also responded to 
treatment. Beside high levels of serum thymidine kinase [4], a short L D T 
[2] as well as a diffuse bone marrow involvement [3] were identified as 
risk factors for progression in early stage B-CLL. 
Thus, in consequence of the results of this pilot study, a phase I I I trial 
on IFN-a in early stage B-CLL at high risk for progression was initiated. 
IFN-a in Early Stage B-CLL - Preliminary Results of a Phase III Trial 
Materials and Methods 
Inclusion Criteria and Study Design 
Patients who were not older than 75 years and having a morphologically and immu-
nologically proven, previously untreated B-CLL in Binet stage A were included in this trial. 
A l l the patients had to give their written informed consent. The lymphocyte count had to be 
< 100,000 l /u l . Patients were stratified by risk factors. A diffuse bone marrow infiltration and 
a L D T < 12 months and /or serum levels of thymidine kinase > 5 U/l qualified for the 
high-risk group. Patients in the high-risk group were randomized into an arm A with IFN-a 
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therapy, and an arm B without treatment. Patients with a nodular bone marrow infiltration, 
and all those with a diffuse infiltration but without an additional risk factor, were allocated to 
the low-risk group (arm C. no treatment). The aims of the study are freedom from progres-
sion and long-time survival. 
Patient Characteristics 
At the time of this analysis (Apri l 15, 1992), 13 patients were evaluable in arm A, 13 
patients in arm B, and another 28 patients in arm C. Median age of the three study arms was 
60 years. No severe concomitant diseases were evident. Median serum levels of the thy-
midine kinase were 7 U/l in arm A and 8.3 U/l in arm B, but 3.8 U/l in arm C (p < 0.01). 
Median L D T was 10 months in arm A, 24.5 months in arm B (no significant difference), and 
42 months in arm C (p < 0.05). 
Treatment 
High-risk patients randomized into arm A were treated with IFN-a (Intron A * ) subcu-
taneously. The planned dosage per week was 3 x 5 x 106 I U IFN-oc. Dose modifications for 
individual reasons like toxic side effects were allowed. Dose escalation up to 3 x 8 x 1()6 IU 
IFN-a was proposed in case of increasing lymphocyte counts during IFN treatment. 
Definitions 
Complete remission (CR) was defined as the complete disappearance of peripheral 
signs of C L L , i.e. lymphocytosis, lymphadenopathy, and hepatosplenomegaly. Partial remis-
sion (PR) was defined as the 50% or more reduction of the tumor load. Beside an upstaging 
to Binet B or Binet C disease, progression of disease was defined as the increase of the total 
lymphocyte count > 100,000 1/ul, or occurrence of new enlarged lymph nodes, or increase of 
prior enlarged lymph nodes, liver, or spleen. 
Results 
Status of Disease 
Five out of the 13 high-risk patients with IFN-a treatment (arm A) 
achieved a PR with time to reach remission varying from 1 to 5 months. 
Two patients had stable disease. The remaining 6 patients had progressive 
disease, and 2 of them had to be treated with conventional chemotherapy. 
It has to be noted, however, that for individual reasons only 45% of the 
patients in arm A received the 100% dosage of IFN-a according to the 
study protocol, i.e. 3 x 5 x 106 IU/week. In arm B (high risk, no treatment) 
7 out of 13 patients had stable disease, whereas the disease was progres-
sive in the remaining 6 patients. Four of the latter ones had to be treated 
with conventional chemotherapy. In contrast to the high-risk patients, the 
vast majority (23 out of 28 patients) of the low-risk patients had stable dis-
ease. Even though 5 patients experienced disease progression, none of 
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Table 2. Results 
Arm A: n = 13 treatment with IFN-a, 'high-risk*1 
PR 5 
NC 2 
PD 6, with 2 in need for chemotherapy 
Arm B: n = 13 no treatment, 'high risk' 
PRO 
NC 7 
PD 6, with 4 in need for chemotherapy 
Arm C: n = 28 no treatment, l o w risk' 
PRO 
NC 23 
PD 5, with 0 in need for chemotherapy 
PR = partial remission; NC = no change; PD = progressive disease. 
1 Only 45% of the patients were treated with the 100% dosage of IFN-a (3 x 5 x 10 6 IU sc) 
as outlined in the protocol. 
them was in need for chemotherapy. Time until progression differed sig-
nificantly (p < 0.05) between the high-risk and the low-risk patients. No 
influence of IFN-a became evident so far, while median time to progres-
sion was 12 months in arm A, and 13 months in arm B. The median was 
not yet reached in arm C within an observation time of 30 months. The 
results are listed in table 2. 
Toxic Side Effects 
IFN-a was well tolerated in the majority of patients. Flu-like symp-
toms, alopecia, and weight loss did not exceed WHO grade I I toxicity. A 
slight increase of serum levels of GOT and creatinine, respectively, was 
observed only in 1 patient (WHO grade I toxicity). Nevertheless, 3 
patients were excluded from further IFN-a treatment due to toxic side 
effects. Two of them experienced depression (WHO grade I I ) . One patient 
suffered from diarrhea and nausea to be classified as WHO grade I I I toxic-
ity. This particular patient had to definitely discontinue IFN-a therapy 
despite a dosage reduction from 3 x 3 x 10 6 FU IFN-a/week to 3 x 1 x 106 
IU/week, and despite concomitant treatment with antiemetic drugs. The 
toxic side effects are listed in table 3. 
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Table 3. Toxic side effects 
76 
Side effects W H O grade 
I I I I I I IV 
Fever 2 1 
Myalgia 5 
Headache 1 
Alopecia 4 
Weight loss 2 
Diarrhea 1 1 
Nausea 2 1 
Dizziness 1 2 
Depression 1 2 
SGOT 1 
Creatinine 1 
Only 1 patient with W H O > I I toxicities; 3 patients off treatment due to toxicities. 
Discussion 
The preliminary results of this randomized trial on IFN-a in early 
stage B-CLL seem to confirm the concept of stratification by risk factors. 
Five out of 28 patients at low risk for progression had progressive disease, 
whereas 12 out of 26 patients at high risk (13 patients in arm A, another 13 
patients in arm B) had progressive disease. Moreover, a significant differ-
ence in time until progression became evident. In the two high-risk 
groups, median time to progression was 12 and 13 months, respectively. In 
the low-risk group, however, the median was not yet reached within an 
observation period of 30 months. Therefore, the occurrence of a diffuse 
bone marrow infiltration together with a LDT < 12 months and/or levels of 
serum thymidine kinase > 5 U/l define in fact a condition of high risk for 
progression in early stage B-CLL. 
Antileukemic effects of IFN-a were evident in some patients. Five out 
of 13 patients in our study achieved a PR. Foon et al. [9] reported on 2 
patients out of 12 achieving a PR, and O'Connell et al. [16] found 1 PR in 4 
patients. Somewhat better results were obtained by Pangalis et al. [6] who 
reported on 5 out of 10 patients achieving a remission (1 CR and 4 PR). In 
that particular study, the 4 patients who attained a PR had Binet stage A dis-
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ease and had not recieved prior chemotherapy. A high rate of responding 
patients was reported by Rozman et al. [8]. A l l the 10 patients examined in 
their study had a transient reduction of the number of circulating lympho-
cytes. Moreover, an increase of the granulocyte count was detected in 8 
patients. Interestingly, all the patients in the study of Rozman et al. had 
Binet stage A disease without prior treatment, according to Rai stages O - I . 
While some efficacy of IFN-a in early stage B-CLL is obvious, little 
is known until today about the mechanisms of action. Efficacy of IFN-a 
may depend on the number of receptors on the target cells. While low 
numbers of receptors were found in advanced stage B-CLL, high numbers 
detected in early stage could be prerequisite for the antileukemic effects of 
IFN-a [17]. Moreover, induction of HLA-DR expression with activation 
of monocytes [7], recruitment of N K cells [16], and a relative increase of 
the T4-positive lymphocyte subset [16] during IFN-a treatment were 
reported. These latter findings may also be related to the responsiveness of 
early stage B-CLL to IFN-a. 
IFN-a may interact with other cytokines. Tumor necrosis factor-a 
(TNF-a) was found to act as an autocrine growth factor in B-CLL [18, 
19], and high serum levels of TNF-a are thought to be a characteristic fea-
ture in early stage disease [20]. The disruption of the TNF-a dependent 
proliferation in B-cell malignancies by IFN-a was postulated to represent 
the mechanism by which IFN-a could counteract cell proliferation [21]. 
However, IFN-a does not seem to have an influence on the production of 
TNF-a in B-CLL cells, and furthermore, it enhances TNF-a release in 
hairy cell leukemia [22]. Thus, efficacy of IFN-a seems to be mediated by 
other pathways. 
The prognostic impact of the response to IFN-a treatment in early 
stage B-CLL remains undefined, since no studies on the long-time follow-
up of the responding patients were published so far. A larger number of 
patients and a follow-up for several years in our study may contribute to 
elucidate that point. 
Future Concepts 
So far, efficacy of IFN-a in B-CLL was shown in a number of pilot 
studies (see table 1). A consistent observation was that the effectiveness of 
IFN-a was higher in early stage than in advanced stage disease. Induction 
of remission in case of a low tumor load is therefore possible, but the ben-
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efit with respect to survival and freedom from progression remains to be 
defined. 
Maintenance of remission is another goal in the treatment of B-CLL. 
IFN-a was shown to prolong the duration of remission in multiple mye-
loma after prior 'inductive' chemotherapy [23]. In analogy, IFN-a could 
provide the chance of maintained remission in early as well as in advanced 
stages of B-CLL after conventional chemotherapy. Montserrat et al. [24] 
published first results of a pilot study, in which the tumor load of 11 
patients with early stage B-CLL was reduced by intermittent chlorambucil. 
Then, IFN-a was administered, and the quality of remission was improved 
in 5 patients. Additional studies on IFN-a after prior chemotherapy in 
advanced stage B-CLL are urgently warranted. 
IFN-a is currently examined in combination with 5-fluorouracil (5-
FU) in a number of trials on solid tumors of the gastrointestinal tract. The 
rationale of these trials is to modify the cytotoxicity of 5-FU by IFN-a 
[25]. Modulation of cytotoxicity could be an approach also in B-cell 
malignancies. Pini and Foa [26] reported on 2 patients with B-CLL having 
received chlorambucil in combination with IFN-a. The progressive dis-
ease in both patients could not be further controlled by chlorambucil 
alone. But, the additional application of IFN-a led to a reduction of circu-
lating lymphocytes followed by a stable disease. This preliminary observa-
tion should initiate pilot studies to assess the feasibility and efficacy of 
combined treatments with IFN-a and cytotoxic agents. 
A number of cytokines seem to be involved in the regulation of cell 
growth in B-CLL. Interleukin-4 (IL-4) shows antiproliferative activity 
[27], while, for example, TNF-a and interleukin-2 (IL-2) are known to 
stimulate proliferation [18, 19, 28]. Therefore, studies on the combination 
of IFN-a with IL-4 are needed and might be helpful for understanding the 
cytokine network in B-CLL. 
In summary, IFN-a provides some antileukemic activity in B-CLL. 
However, its modes of action and most effective modalities of treatment 
still remain to be clarified. 
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